Pharmaceutical litigation often demands more than showing that a drug was prescribed and complications followed. Attorneys must prove causation, establish timelines, and dismantle alternative defense theories with clarity and precision.
This case study illustrates how Trivent Legal’s Expert Intelligence solution turned fragmented pharmacy histories and complex medical files into a litigation-ready evidence package enabling attorneys to confront Merck’s defense head-on in the Fosamax (alendronate sodium) mass tort.
Background
Fosamax (alendronate sodium), a bisphosphonate manufactured by Merck, was widely prescribed for osteoporosis and osteopenia, particularly among aging populations seeking to improve bone mass. While effective in strengthening bone density, its long-term use became linked to severe complications, including atypical femur fractures, osteonecrosis of the jaw (ONJ), and debilitating musculoskeletal pain. These adverse outcomes led to thousands of lawsuits across the U.S., with plaintiffs alleging that Merck failed to provide adequate warnings and delayed disclosure of long-term risks. The litigation faced unique hurdles: patients often had overlapping prescriptions with other bisphosphonates such as Actonel and Boniva, making causation analysis challenging; pharmacy records were incomplete, particularly prior to 2008; and defense strategies frequently pointed to alternative causes such as age-related degeneration or periodontal disease. To overcome these obstacles, plaintiffs’ attorneys needed clear, defensible timelines and strong medical correlation to directly link injuries to Fosamax.
Common Challenges in the MDL
- Complex Records: Patients frequently used overlapping bisphosphonates (Fosamax, Actonel, Boniva), complicating causation analysis.
- Complication Mapping: Proving femur fractures and ONJ stemmed directly from Fosamax required strong medical correlation.
- Record Gaps: Pharmacy histories were often incomplete, especially before 2008.
- Defense Strategy: Merck emphasized age-related degeneration and periodontal disease as alternative causes.
Attorneys needed expert intelligence to cut through noise, fill data gaps, and prove Fosamax’s role.
Trivent Legal’s Medico-Legal Approach
Using our Expert Intelligence Solution, we combined technology-driven review with physician oversight to deliver clarity from complexity.
Case Screening & Intake Review: Captured indication for Fosamax, dosage history, and reported complications.
Complication Coding: Applied ICD-9/10 codes for fractures, ONJ, and other Fosamax-related injuries.
Chronology Building: Structured medical files into sequenced, hyperlinked timelines with Bates references.
Gap Identification: Flagged missing pharmacy details while maintaining momentum in case preparation.
Deliverables: Attorneys received merged records, intake reports, and medical chronologies ready for litigation.
Case Spotlight: Fosamax and Femoral Fractures
Drug History
- Fosamax prescribed from 2002 to 2011 in weekly 35 mg and 70 mg doses.
- Concurrent Actonel prescriptions during overlapping periods.
- Pharmacy records incomplete; Trivent extracted prescription data from medical charts to fill gaps.
Complications
- Right femur fracture confirmed by radiology (date documented).
- Left femur degeneration and stress fracture documented 2009–2010 via NM bone scan and CT, culminating in closed fracture (date documented).
Treatment Pathway
- Orthopedic surgery: Right subtrochanteric hip fracture repaired with intramedullary fixation.
- Rehabilitation: Physical therapy spanning two years, covering both femoral fractures.
- Supportive care: Use of walker, partial weight-bearing instructions, long-term pain management.
Trivent Legal’s Support
- Created a nine-year exposure timeline, mapping Fosamax prescriptions against fracture onset and progression.
- Cross-linked diagnostic imaging, surgical interventions, and rehabilitation notes to drug intake history.
- Identified gaps in pharmacy documentation, clearly annotated for attorney follow-up.
- The result was a defensible chronology showing temporal correlation between Fosamax use and atypical femoral fractures.
Outcome & Impact
- Causation Strengthened: Attorneys presented a medically validated progression of injury directly linked to Fosamax.
- Preparation Time Reduced: QA-audited chronologies cut through 1,000+ pages of records.
- Defense Neutralized: Alternative explanations (age, periodontal disease) were countered with sequenced, evidence-based timelines.
- Case Readiness Enhanced: Attorneys entered negotiations and litigation with clear, defensible evidence packages.
Conclusion
The Fosamax litigation demonstrates that mass tort success requires more than volume—it requires precision. Attorneys must separate relevant from irrelevant, fill gaps, and link complications to drug exposure in a way that withstands scrutiny. At Trivent Legal, we empower attorneys to turn data into strategy, and complexity into courtroom clarity ensuring that justice is backed by evidence.